What question did this study set out to answer?

Evaluate the effectiveness of modified BFM therapy in children with high-risk acute lymphoblastic leukemia.

Modified BFM Therapy for Children with Previously Untreated Acute Lymphoblastic Leukemia and Unfavorable Prognostic Features

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows improved event-free survival in children with high-risk acute lymphoblastic leukemia, suggesting therapy effectiveness.

Evaluate the effectiveness of modified BFM therapy in children with high-risk acute lymphoblastic leukemia.
Tested in a cohort of 209 children newly diagnosed with ALL and specific high-risk features.
Modified therapy based on reported toxicity and protocol requirements during intensive phases.
Cumulative doses monitored to ensure adherence to treatment protocols.
195 patients achieved remission (93.3%).
4-year event-free survival was 62% (+/- 3.7%) with a median follow-up of 40 months.
Only one isolated CNS relapse observed among the participants.

Gaynon et al. (1988) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows improved event-free survival in children with high-risk acute lymphoblastic leukemia, suggesting therapy effectiveness.